163 related articles for article (PubMed ID: 18281665)
1. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Reardon DA; Fink KL; Mikkelsen T; Cloughesy TF; O'Neill A; Plotkin S; Glantz M; Ravin P; Raizer JJ; Rich KM; Schiff D; Shapiro WR; Burdette-Radoux S; Dropcho EJ; Wittemer SM; Nippgen J; Picard M; Nabors LB
J Clin Oncol; 2008 Dec; 26(34):5610-7. PubMed ID: 18981465
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of everolimus in pediatric patients with refractory solid tumors.
Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
[TBL] [Abstract][Full Text] [Related]
15. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Groen HJ; de Vries EG; Wynendaele W; van der Graaf WT; Fokkema E; Lechuga MJ; Poggesi I; Dirix LY; van Oosterom AT
Clin Cancer Res; 2001 Dec; 7(12):3928-33. PubMed ID: 11751484
[TBL] [Abstract][Full Text] [Related]
16. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
Yamada S; Bu XY; Khankaldyyan V; Gonzales-Gomez I; McComb JG; Laug WE
Neurosurgery; 2006 Dec; 59(6):1304-12; discussion 1312. PubMed ID: 17277694
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
Dreyer ZE; Kadota RP; Stewart CF; Friedman HS; Mahoney DH; Kun LE; McCluggage CW; Burger PC; Kepner J; Heideman RL;
Neuro Oncol; 2003 Oct; 5(4):261-7. PubMed ID: 14565163
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.
Geoerger B; Doz F; Gentet JC; Mayer M; Landman-Parker J; Pichon F; Chastagner P; Rubie H; Frappaz D; Le Bouil A; Gupta S; Vassal G
J Clin Oncol; 2008 Sep; 26(27):4394-400. PubMed ID: 18802151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
